FORMULATION, OPTIMIZATION AND INVITRO EVALUATION OF GASTRO RETENTIVE SUMATRIPTAN SUCCINATE TABLETS
G. Pratap Kumar*, Venkata Naga Swetha M. and T. Murali Krishna
The present work was aimed at developing effervescent floating tablets of Sumatriptan succinate using natural and synthetic polymers. Gas generating agents and diluent, glidant and lubricants are used in Sumatriptan succinate floating tablets with effervescent method were also formulated. Migraine is a common disorder characterized by a unilateral headache, which is often associated with nausea, vomiting, gastrointestinal disturbance and extreme sensitivity to light and sound. Sumatriptan succinate is the first member of a new class of anti-migraine compounds that act as a specific and selective 5-hydroxytryptamine-1 receptor agonist. Sumatriptan has low bioavailability after oral administration (about 15%), with a large inter-individual variation, although not affected by concomitant food intake. The dose is 50-100 mg orally. Tmax is reached at approximately 2 h and is slightly delayed by the presence of food and during an acute migraine attack. Sumatriptan succinate, an anti migraine agent, has been widely used for the treatment of anti migraine. It has been reported, however, that the duration of anti migranie action after a single oral dose of sumatriptan succinate is only 2-4 hr. Clinical use requires a dose of 50-100 mg to be taken onces a day but NMT 200mg/day. Sumatriptin succinate has a pH of 1.2 & remains stable at stomach environment. Frequency of dosing will be minimized. Objectives:
1. To increase patient compliance by preventing repetitive administration of the dosage forms.
2. To prolong drug release in a sustained manner using HPMC-K4M as the rate controlling polymer
To increase the gastric residence time of Sodium bicarbonate by developing floating drug delivery systems. To evaluate the prepared dosage forms by carrying out suitable quality control tests.
[Full Text Article]